Lupin announced
that it has received approval for its Droxidopa Capsules, 100 mg, 200 mg, and
300 mg, from the United States Food and Drug Administration, to market a generic equivalent of
Northera Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA. The product will be
manufactured at Lupin's facility in Nagpur, India.
Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, are indicated for the treatment of orthostatic dizziness, lightheadedness, or the feeling that you are about to black out in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine betahydroxylase deficiency, and non-diabetic autonomic neuropathy.
Droxidopa Capsules (RLD: Northera) had estimated annual sales of USD 352 million in the U.S. (IQVIA MAT December 2020)
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
